🏅 FDA Orphan Designation

POTELIGEO

mogamulizumab

Manufacturer: Kyowa Kirin Pharmaceutical Development Inc.

Indicated for:

Indolent primary cutaneous T-cell lymphomaOrphanMycosis fungoides and variantsEEC syndrome and related disorders

FDA-Approved Indications (3)

Indolent primary cutaneous T-cell lymphomaOrphan Designation

POTELIGEO is indicated for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or Sï¿½zary syndrome (SS) after at least one prior systemic therapy.

Mycosis fungoides and variants

indicated for the treatment of adult patients with relapsed or refractory mycosis fungoides after at least one prior systemic therapy

Population: adults

EEC syndrome and related disorders

indicated for the treatment of adult patients with relapsed or refractory Sézary syndrome after at least one prior systemic therapy

Population: adults

Indications & Usage

1 INDICATIONS AND USAGE POTELIGEO is indicated for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after at least one prior systemic therapy. POTELIGEO is a CC chemokine receptor type 4 (CCR4)-directed monoclonal antibody indicated for the treatment of adult patients with relapsed or refractory mycosis fungoides or Sézary syndrome after at least one prior systemic therapy ( 1 ).

💙 Support Programs

View all →

POTELIGEO

Kyowa Kirin

Copay card ↗Apply ↗

Where shown, WAC (Wholesale Acquisition Cost) is an estimate only — your actual cost depends on your insurance plan. Always verify pricing with your pharmacy or insurer.

Medical disclaimer: This information is for educational purposes only. Always consult a qualified healthcare provider before making treatment decisions. Data sourced from FDA and current as of our last update.